Similarly, dual-acting PPARα/γ agonists (glitazars), such as tesaglitazar, also beneficially affected the glucose metabolism, insulin resistance and atherogenic dyslipidaemia in patients with type 2 diabetes13–15. Here, PPARA is linked to Insulin resistance.